Clinical Trial Update: A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

The phase 1/2 trial of MDK-703 in patients with solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MDK-703

Snippet

Sponsor: Medikine, Inc. | Conditions: Advanced or Metastatic Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED